Dimerix Stock

Dimerix P/FCF

The P/FCF (Price-to-Free-Cash-Flow Ratio) of Dimerix (DXB.AX) as of Sep 4, 2026 is 7.61. In the previous year, P/FCF (Price-to-Free-Cash-Flow Ratio) was -42.34 — a change of -117.98% (higher).

P/FCF

7.61

YoY

-117.98%

Last updated:

P/FCF (Price-to-Free-Cash-Flow Ratio) of Dimerix is 2026 7.61 . P/FCF (Price-to-Free-Cash-Flow Ratio) of Dimerix was 2025 -42.34 . It decreases by -117.98% higher compared to the previous year.

The Dimerix P/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/FCF
Date
P/FCF
Jan 1, 2018
-92.04 AUD
Jan 1, 2019
-107.77 AUD
Jan 1, 2020
-62.95 AUD
Jan 1, 2021
-46.66 AUD
Jan 1, 2022
-22.10 AUD
Jan 1, 2023
-23.34 AUD
Jan 1, 2024
-42.34 AUD
Jan 1, 2025
7.61 AUD
The Dimerix P/FCF history
YEARP/FCFYoY
7.61-117.98%
-42.34+81.36%
-23.34+5.62%
-22.10-52.63%
-46.66-25.88%
-62.95-41.59%
-107.77+17.09%
-92.04-42.18%
-159.18-26.03%
-215.19-59.89%
-536.55+2.91%
-521.40
Access this data via the Eulerpool API

Dimerix Stock analysis

What does Dimerix do? Dimerix Ltd is an Australian biotechnology company specializing in the development of innovative therapies for various medical needs. Their business model is based on identifying new targets for drug development, often through collaborations with other biotech or pharmaceutical companies. Dimerix focuses on cancer therapy, utilizing their innovative platform technology to identify and test a variety of drug candidates. They also have a pipeline of medications for kidney and lung diseases, as well as inflammation and pain. Dimerix actively seeks partnerships with other companies and research institutions to bring innovative therapies to market. One of their key products, DMX-200, is currently in phase II clinical trials for the treatment of kidney diseases and has shown promising results. Overall, Dimerix is well-positioned to continue bringing successful therapies to market in the future. Dimerix is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Dimerix stock

P/FCF (Price-to-Free-Cash-Flow Ratio) of Dimerix is 7.61 in 2026.

P/FCF (Price-to-Free-Cash-Flow Ratio) of Dimerix changed from -42.34 to 7.61, representing a -117.98% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of P/FCF (Price-to-Free-Cash-Flow Ratio) Dimerix since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Free-Cash-Flow ratio measures how much investors pay for each unit of free cash flow. A lower ratio may indicate better value.

P/FCF = Market Capitalization / Free Cash Flow

To evaluate P/FCF (Price-to-Free-Cash-Flow Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/FCF (Price-to-Free-Cash-Flow Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/FCF (Price-to-Free-Cash-Flow Ratio)'s Dimerix with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Valuation — Dimerix

All Key Metrics — Dimerix